Fig. 1: SARS-CoV-2 variant vaccine design and characterization. | npj Vaccines

Fig. 1: SARS-CoV-2 variant vaccine design and characterization.

From: Potent neutralization of SARS-CoV-2 variants by RBD nanoparticle and prefusion-stabilized spike immunogens

Fig. 1

A Graphical representation of the production and characterization of SARS-CoV-2 RBD-NP vaccines, created with BioRender.com. B Molecular surface representation of the SARS-CoV-2 HexaPro trimer in the prefusion-stabilized conformation in gray19 (PDB: 6XKL). N-linked glycans in dark blue. A single RBD is boxed and expanded with bound hACE2 receptor61 (PDB: 6M0J) and CR3022 Fab (PDB: 6W41)23 shown for reference. Pink spheres indicate β and γ RBD mutations (K417N/T, E484K, and N501Y). Purple spheres indicate stabilizing Rpk9 mutations (Y365F, F392W, and V395I). C Representative DLS of 8 monovalent RBD-NPs with and without Rpk9 mutations. D Structural models of 8 monovalent RBD-NPs and 3 prefusion-stabilized HexaPro trimers alongside representative nsEM micrographs of each immunogen. All graphical representations of proteins made using ChimeraX61.

Back to article page